Alzheimer's disease (AD) is associated with degenerative changes and loss of various populations of neurons in the brain. Since neurotrophic factors regulate neuronal survival and maintenance of function, such factors may provide avenues for the development of effective treatment for AD. By preventing or attenuating neuronal degeneration, neurotrophic factors may slow down or stop the progression of the disease and associated cognitive disturbances. Based on its ability to prevent degenerative changes of cholinergic neurons induced by experimental lesions in rats and monkeys, nerve growth factor (NGF) is presently under consideration as experimental treatment for AD.
One specific aim of this application, related to NGF's long-term effects and the feasibility of slow-releasing implants, will provide additional information valuable for clinical use of NGF. However, the value of NGF in the treatment of AD is limited by its specificity for forebrain cholinergic neurons. The recent discovery of homologs of NGF, brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), established the family of neurotrophins. These neurotrophins affect a variety of peripheral and central neurons and their effects overlap for some neuronal populations but differ for others. Recent findings, which provide the basis for this application, indicate that posttranslational modifications of the neurotrophins influence their biological activities and their specificity to act on subsets of neuronal populations. Therefore, it is proposed to prepare modified molecular forms of the neurotrophins either by recombinant expression or by specific protease treatment. Biological effects of these modified neurotrophins will then be characterized initially in neurotrophin receptor assays and in cell culture assays.Biologically active modified neurotrophins selected by the in vitro assays will then be tested in vivo in rat brain lesion models mimicking selective degenerative changes occurring in AD brains. These modified neurotrophins will be tested for their ability to counteract molecular, morphological, and behavioral deficits induced by the experimental lesions. Additional studies, using immunohistochemistry and retrograde transport methodologies, aim at identifying previously unknown neurotrophin-responsive cell populations. In summary, this program project aims at identifying modified neurotrophins able to specifically affect survival and function of neuronal populations degenerating in Alzheimer's disease. It is hoped that the studies will lead to the discovery of modified neurotrophins with either restricted or broadened biological specificity when compared with their natural counterparts and in the identification of molecules most promising for further development as therapeutics in Alzheimer's disease. The program project joins established academic and industrial scientists with a record of previous collaboration in the pharmacological exploitation of neurotrophic factors for developing effective treatment for AD and cognitive diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010480-03
Application #
3091344
Study Section
Neuroscience, Behavior and Sociology of Aging Review Committee (NBSA)
Project Start
1991-09-30
Project End
1994-07-31
Budget Start
1993-08-15
Budget End
1994-07-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
Organized Research Units
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Wong, Philip C; Cai, Huaibin; Borchelt, David R et al. (2002) Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5:633-9
Wong, P C; Cai, H; Borchelt, D R et al. (2001) Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. J Mol Neurosci 17:233-57
Qiao, X; Chen, L; Gao, H et al. (1998) Cerebellar brain-derived neurotrophic factor-TrkB defect associated with impairment of eyeblink conditioning in Stargazer mutant mice. J Neurosci 18:6990-9
Knusel, B; Gao, H; Okazaki, T et al. (1997) Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. Neuroscience 78:851-62
Hughes, P E; Alexi, T; Hefti, F et al. (1997) Axotomized septal cholinergic neurons rescued by nerve growth factor or neurotrophin-4/5 fail to express the inducible transcription factor c-Jun. Neuroscience 78:1037-49
Sukhov, R R; Cayouette, M H; Radeke, M J et al. (1997) Evidence that perihypoglossal neurons involved in vestibular-auditory and gaze control functions respond to nerve growth factor. J Comp Neurol 383:123-34
Koliatsos, V E; Price, D L (1996) Axotomy as an experimental model of neuronal injury and cell death. Brain Pathol 6:447-65
Qiao, X; Hughes, P E; Venero, J L et al. (1996) NT-4/5 protects against adrenalectomy-induced apoptosis of rat hippocampal granule cells. Neuroreport 7:682-6
Chan, K M; Lam, D T; Pong, K et al. (1996) Neurotrophin-4/5 treatment reduces infarct size in rats with middle cerebral artery occlusion. Neurochem Res 21:763-7
Qiao, X; Hefti, F; Knusel, B et al. (1996) Selective failure of brain-derived neurotrophic factor mRNA expression in the cerebellum of stargazer, a mutant mouse with ataxia. J Neurosci 16:640-8

Showing the most recent 10 out of 43 publications